These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38017575)

  • 1. Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022.
    Wu J; Yang Y; Yu J; Qiao L; Zuo W; Zhang B
    Orphanet J Rare Dis; 2023 Nov; 18(1):368. PubMed ID: 38017575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
    Bunnik EM; Aarts N
    BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021.
    Maeda H; Uchida M; Kusano M; Tsukamoto K; Yamanoi M
    Clin Pharmacol Ther; 2022 Oct; 112(4):817-823. PubMed ID: 35569010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Before It's Too Late: Multistakeholder Perspectives on Compassionate Access to Investigational Drugs for Pediatric Patients With Cancer.
    Gerasimov E; Donoghue M; Bilenker J; Watt T; Goodman N; Laetsch TW
    Am Soc Clin Oncol Educ Book; 2020 May; 40():1-10. PubMed ID: 32412804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compassionate Drug Use - Time Arising for a New Law in Bulgaria in the Era of COVID-19.
    Dzhafer N; Papathanasiou JV
    Folia Med (Plovdiv); 2020 Sep; 62(3):592-596. PubMed ID: 33009760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Which efficacy trials for drugs for rare diseases?].
    Traversa G; Trotta F
    Epidemiol Prev; 2017; 41(5-6):318-319. PubMed ID: 29119773
    [No Abstract]   [Full Text] [Related]  

  • 9. Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.
    Stout J; Smith C; Buckner J; Adjei AA; Wentworth M; Tilburt JC; Master Z
    PLoS One; 2021; 16(12):e0261478. PubMed ID: 34919568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
    Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
    Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
    McKee AE; Markon AO; Chan-Tack KM; Lurie P
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
    Goldman SA
    Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
    Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE
    Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program.
    Speers MA
    Pharmaceut Med; 2019 Apr; 33(2):89-98. PubMed ID: 31933253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
    Kesselheim AS; Myers JA; Avorn J
    JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs.
    Gould P; Salam T; Kimberly L; Bateman-House A; Fernandez Lynch H
    JAMA Netw Open; 2022 Nov; 5(11):e2239766. PubMed ID: 36318206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded access to investigational drugs in psychiatry: A systematic review.
    Vermeulen SF; Polak TB; Bunnik EM
    Psychiatry Res; 2023 Nov; 329():115554. PubMed ID: 37890403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.